Slide 1: OraSure: The Facts
OraSure: The Facts Altai Capital has made several misleading claims that serve as the basis for its efforts to replace two independent directors on OraSure’s Board. This presentation sets the record straight on the facts. March 2026 Exhibit 99.1
Slide 2: Strategy & Growth Outlook
Strategy & Growth Outlook OraSure is executing a focused strategy with near-term catalysts expected to drive revenue growth, margin expansion, and profitability Public health funding environment stabilizing across U.S. and international markets; recovery in testing volumes expected as programs norma
Slide 3: Total Shareholder Return
1-Year 3-Years 5-Years Total Shareholder Return OraSure outperforms the median when compared to Altai’s own selected peer set1 In-line Outperforms In-line Outperforms OraSure has outperformed the peer median by ~40% during Carrie Eglinton Manner’s tenure as CEO, and the Company remains focused on en
Slide 4: Capital Allocation
Capital Allocation OraSure takes a disciplined approach to capital allocation, placing focus on high-ROI growth, maintaining a debt-free balance sheet, and returning capital to shareholders Average repurchase price in 2025 of $2.85, well below Altai’s $4.54–$6.60/share valuation, contradicting Altai
Slide 5: Strengthening Operations
Strengthening Operations OraSure’s operations reflect a strategic transition and repositioning for revenue acceleration and continued margin expansion Gross margin1 is improving SG&A Continues to Be Rationalized Key cost actions driving efficiencies Operating capacity +260bps expansion over 3 years
Slide 6: M&A Track Record
M&A Track Record OraSure has deployed capital into pre-commercial diagnostic platforms with defined regulatory pathways Deals structured to align investment with value realization Altai seemingly assigns zero value to assets prior to regulatory outcome, inconsistent with how diagnostics assets are v
Slide 7: Director Stock Ownership
Director Stock Ownership Stock ownership of OraSure's independent directors is above the median of Altai’s selected peers and demonstrates strong shareholder alignment 2x Peers OraSure’s independent directors own more than double the median of peer Boards, in the aggregate and on a per-director basi
Slide 8: Executive Compensation & Alignment
Executive Compensation & Alignment OraSure’s CEO compensation is predominantly performance-based and aligned with shareholder outcomes Representing best practices ISS has recommended “FOR” say-on-pay at the last two annual meetings ~87% of CEO Carrie Eglinton Manner’s pay consists of performance-bas
Slide 9: Strategic Alternatives
Strategic Alternatives The Board regularly evaluates opportunities to maximize shareholder value and continues to do so, but now is not the right time for Altai Capital to pressure the Company into a sale process from inside the boardroom $13bn+ in strategic M&A transactions overseen by OraSure’s di
Slide 10: Rishi Bajaj’s Track Record
Rishi Bajaj’s Track Record The track record of Rishi Bajaj, Altai’s founder and principal, emphasizes speculative, transaction-driven outcomes rather than maximizing long-term shareholder value Digimarc — Mr. Bajaj’s only current public directorship — has declined (65%) since his appointment1 FY25 r
Slide 11: Altai’s Engagement History
Altai’s Engagement History OraSure has consistently engaged in good faith and proposed multiple constructive settlement solutions while Mr. Bajaj has been singularly focused on obtaining a Board seat for himself to press for a sale strategy within the boardroom The Board conducted a thorough evaluat
Slide 12: Appendix
Appendix
Slide 13: Reconciliation of Non-GAAP Gross Margin
Reconciliation of Non-GAAP Gross Margin1 Year Ended 2025 Year Ended 2022 gg Revenue $ $115,021 $ 387,479 GAAP Cost of products and services sold 66,823 239,041 GAAP Gross Margin 41.9% 38.3% Stock compensation 707 331 Amortization of acquisition-related intangible assets - 528 Transformation related
Slide 14: Forward-Looking Statements
Forward-Looking Statements This communication contains certain forward-looking statements, including with respect to products, product candidate development and manufacturing activities, regulatory submissions and authorizations, revenue growth and guidance, expected revenue from government orders,